Jim Simons Rezolute, Inc. Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Rezolute, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 378,800 shares of RZLT stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

378,800

Previous 89,700 322.3%

Holding current value

$1.68 Million

Previous $427,000 157.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$2.73 - $5.57 $789,243 - $1.61 Million	289,100 Added 322.3%	378,800 $1.1 Million
Q4 2024 Feb 13, 2025	SELL	$4.08 - $5.96 $769,488 - $1.12 Million	-188,600 Reduced 67.77%	89,700 $427,000
Q3 2024 Nov 13, 2024	BUY	$4.13 - $5.31 $404,240 - $519,737	97,879 Added 54.25%	278,300 $1.35 Million
Q2 2024 Aug 09, 2024	SELL	$2.29 - $5.79 $342,721 - $866,531	-149,660 Reduced 45.34%	180,421 $775,000
Q1 2024 May 13, 2024	BUY	$0.95 - $2.55 $264,741 - $710,621	278,675 Added 542.11%	330,081 $842,000
Q4 2023 Feb 13, 2024	BUY	$0.74 - $1.24 $19,022 - $31,875	25,706 Added 100.02%	51,406 $51,000
Q3 2023 Nov 14, 2023	BUY	$1.32 - $2.1 $5,016 - $7,980	3,800 Added 17.35%	25,700 $34,000
Q2 2023 Aug 11, 2023	BUY	$1.75 - $2.33 $4,375 - $5,825	2,500 Added 12.89%	21,900 $43,000
Q1 2023 May 12, 2023	BUY	$1.79 - $2.87 $3,222 - $5,166	1,800 Added 10.23%	19,400 $37,000
Q4 2022 Feb 13, 2023	BUY	$1.38 - $2.84 $552 - $1,136	400 Added 2.33%	17,600 $36,000
Q3 2022 Nov 14, 2022	SELL	$2.19 - $3.49 $1,533 - $2,443	-700 Reduced 3.91%	17,200 $47,000
Q2 2022 Aug 12, 2022	BUY	$2.6 - $3.85 $46,540 - $68,915	17,900 New	17,900 $58,000

Others Institutions Holding RZLT

# of Institutions

Shares Held

39.7M

Call Options Held

402K

Put Options Held

19.4K

View Full List

About Rezolute, Inc.

Ticker RZLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,600
Market Cap $172M
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...

More about RZLT

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account